Get the Stockscreener App
36.80
4.31%
1.52
After Hours:
36.80
Rapt Therapeutics Inc stock is traded at $36.80, with a volume of 537.81K.
It is up +4.31% in the last 24 hours and up +25.17% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$35.28
Open:
$35.35
24h Volume:
537.81K
Relative Volume:
1.14
Market Cap:
$1.02B
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-12.07
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
+6.77%
1M Performance:
+25.17%
6M Performance:
+322.02%
1Y Performance:
+346.60%
1-Day Range:
$35.27
$38.45
1-Week Range:
$34.01
$38.45
52-Week Range:
$5.6652
$42.39
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
36.80 | 977.64M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-20-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-26-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Rapt Therapeutics (NASDAQ:RAPT) Trading Up 4.9%Here's Why - MarketBeat
BVF Inc. IL Trims Holdings in Rapt Therapeutics $RAPT - MarketBeat
RAPT Therapeutics Announces Major Public Stock Offering - MSN
Rapt Therapeutics $RAPT Shares Sold by Redmile Group LLC - MarketBeat
Can RAPT Therapeutics Inc. (0RA) stock deliver strong annual returnsMarket Risk Summary & Growth Focused Investment Plans - Newser
Published on: 2025-12-04 13:14:54 - Newser
How RAPT Therapeutics Inc. (0RA) stock compares with tech leadersPortfolio Return Summary & Reliable Volume Spike Alerts - Newser
How robust is RAPT Therapeutics Inc. (0RA) stock financial positionVolume Spike & Risk Managed Trade Strategies - Newser
Does RAPT Therapeutics Inc (RAPT) offer a good opportunity for investors? - Setenews
Can RAPT Therapeutics Inc. (0RA0) stock sustain margin levels2025 Biggest Moves & Fast Moving Market Watchlists - Newser
What macro factors could drive RAPT Therapeutics Inc. (0RA0) stock higherRecession Risk & Fast Exit/Entry Strategy Plans - Newser
Why RAPT Therapeutics Inc. (0RA) stock is trending on social mediaFed Meeting & Safe Capital Allocation Plans - Newser
How RAPT Therapeutics Inc. (0RA0) stock performs in easing cyclesRisk Management & Technical Pattern Based Buy Signals - Newser
Published on: 2025-12-02 05:12:24 - Newser
Can RAPT Therapeutics Inc. (0RA) stock ride next bull market cycle2025 Big Picture & Growth Oriented Trade Recommendations - Newser
RAPT Therapeutics announces planned departure of chief medical officer - Investing.com India
RAPT Therapeutics announces planned departure of chief medical officer By Investing.com - Investing.com Nigeria
RAPT Therapeutics Announces CMO Departure - TipRanks
RAPT Therapeutics Announces Departure of Chief Medical Officer - TradingView
Are Smart Investors Making the Right Decision? RAPT Therapeutics Inc (RAPT) - Setenews
RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Market Cap Touched US$830m Last Week, Benefiting Both Individual Investors Who Own 34% as Well as Institutions - 富途牛牛
While institutions invested in RAPT Therapeutics, Inc. (NASDAQ:RAPT) benefited from last week's 17% gain, individual investors stood to gain the most - simplywall.st
Form 8-KCurrent report - ADVFN
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position - MSN
Foresite Capital Management VI LLC Decreases Stock Holdings in Rapt Therapeutics $RAPT - MarketBeat
RAPT Therapeutics Shares Surge on Institutional Confidence and Clinical Progress - AD HOC NEWS
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
RAPT rockets 180% on licensing deal, $150M private placement (update) - MSN
RAPT SEC FilingsRapt Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Will RAPT Therapeutics Inc. stock outperform Nasdaq index2025 Market Overview & Fast Moving Market Watchlists - newser.com
Why RAPT Therapeutics Inc. stock appeals to dividend seekersWeekly Trade Recap & Weekly Breakout Watchlists - newser.com
Why analysts remain bullish on RAPT Therapeutics Inc. stockTrade Analysis Report & AI Powered Buy/Sell Recommendations - newser.com
Can RAPT Therapeutics Inc. stock deliver sustainable ROE2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
D pipelineJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Is RAPT Therapeutics Inc. (0RA) stock a good hedge against inflationRisk Management & Daily Risk Controlled Trade Plans - newser.com
How strong is RAPT Therapeutics Inc. stock revenue growthWeekly Profit Recap & Verified Momentum Watchlists - newser.com
Is RAPT Therapeutics Inc. stock a buy before product launches2025 Biggest Moves & Long-Term Investment Growth Plans - newser.com
How supply shortages influence RAPT Therapeutics Inc. (0RA0) stockJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - newser.com
How RAPT Therapeutics Inc. (0RA0) stock stacks up against competitorsJuly 2025 Selloffs & Risk Controlled Daily Plans - newser.com
Published on: 2025-11-19 17:30:40 - newser.com
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):